February 9, 2021 Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the closing of its upsized initial public offering of 10,350,000 shares of its common stock, which includes 1,350,000 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares, at a public offering price of $17.00 per share. The gross proceeds to Lucira from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were $175.95 million. All of the shares in the offering were sold by Lucira.
Die Brutto-Erlöse aus dem IPO lagen bei 176 Mio $ , die aktuelle Marktkapitalisierung liegt bei 216 Mio $
Fast 80 % der aktuellen Marktkapitalisierung sind durch Cash abgedeckt. ----------- Deutschland schafft sich selbst ab. Traurig aber wahr. |